Display options
Cite
Ghaffar TY, El Naghy S, El Sebaie H, et al. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr. 2009;76(9):895-8doi: 10.1007/s12098-009-0187-x.
Ghaffar, T. Y., El Naghy, S., El Sebaie, H., El Monaiery, M., & Ghaffar, A. Y. (2009). Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian journal of pediatrics, 76(9), 895-8. https://doi.org/10.1007/s12098-009-0187-x
Ghaffar, Tawhida Yassin Abdel, et al. "Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection." Indian journal of pediatrics vol. 76,9 (2009): 895-8. doi: https://doi.org/10.1007/s12098-009-0187-x
Ghaffar TY, El Naghy S, El Sebaie H, El Monaiery M, Ghaffar AY. Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection. Indian J Pediatr. 2009 Sep;76(9):895-8. doi: 10.1007/s12098-009-0187-x. Epub 2009 Nov 04. PMID: 19904504.
Copy Download .nbib Format: NLM
Share it on

Indian J Pediatr. 2009 Sep;76(9):895-8. doi: 10.1007/s12098-009-0187-x. Epub 2009 Nov 04.

Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection.

Indian journal of pediatrics

Tawhida Yassin Abdel Ghaffar, Suzan El Naghy, Hatem El Sebaie, Magda El Monaiery, Aisha Yassin Abdel Ghaffar

Affiliations

  1. Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, Menoufia, Egypt.

PMID: 19904504 DOI: 10.1007/s12098-009-0187-x

Abstract

OBJECTIVE: To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children.

METHODS: Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy. Liver biopsy was performed before and at the end of therapy. Four children had low and three had moderate viremia.

RESULTS: At twelve weeks, two children (28.6%) lost viremia. Another child lost viremia at 52 weeks. ETR was 42.9%. During follow up one relapsed, thus SVR was 28.6%. Children with SVR were the youngest, their mean duration of infection was 4.5 vs 12.7 years in the others. Side effects of both INF & ribavirin was mild, required no reduction in doses.

CONCLUSION: Combination therapy of peg interferon-alpha with ribavirin is well tolerated in children and adolescents studied.

References

  1. Ann Intern Med. 2004 Jan 6;140(1):72-3 - PubMed
  2. Gut. 2005 Jun;54(6):858-66 - PubMed
  3. Pediatr Blood Cancer. 2004 Aug;43(2):185 - PubMed
  4. Hepatology. 2005 May;41(5):1013-8 - PubMed
  5. Am J Trop Med Hyg. 2006 Jul;75(1):16-20 - PubMed
  6. Liver Int. 2004 Dec;24(6):568-74 - PubMed
  7. Science. 1989 Apr 21;244(4902):359-62 - PubMed
  8. N Engl J Med. 1999 Aug 19;341(8):556-62 - PubMed
  9. J Hepatol. 1995 Jun;22(6):696-9 - PubMed
  10. Hepatology. 1993 May;17(5):772-7 - PubMed

Substances

MeSH terms

Publication Types